UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation

British journal of dermatology (1951), 2016-06, Vol.174 (6), p.1174-1178

2016

Volltextzugriff (PDF)

Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study

British journal of dermatology (1951), 2016-09, Vol.175 (3), p.542-548

2016

Volltextzugriff (PDF)

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update

British journal of dermatology (1951), 2020-10, Vol.183 (4), p.628-637

2020

Volltextzugriff (PDF)

Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease

Journal of the European Academy of Dermatology and Venereology, 2020-06, Vol.34 (6), p.1161-1173

2020

Volltextzugriff (PDF)

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017

British journal of dermatology (1951), 2017-09, Vol.177 (3), p.628-636

2017

Volltextzugriff (PDF)

PBI6 Stringent Thresholds of Disease Control Are Associated with Reduced Burden on Paid and Household Work Productivity in Patients with Psoriatic Arthritis during LONG-TERM Treatment with Certolizumab Pegol

Value in health, 2020-12, Vol.23, p.S411-S411

2020

Volltextzugriff (PDF)

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis

British journal of dermatology (1951), 2020-10, Vol.183 (4), p.638-649

2020

Volltextzugriff (PDF)

Psoriasis flare with corticosteroid use in psoriatic arthritis

British journal of dermatology (1951), 2016-01, Vol.174 (1), p.219-221

2016

Volltextzugriff (PDF)

Patient education and screening for psoriatic arthritis is key in the care of patients with psoriasis, whichever method is chosen

British journal of dermatology (1951), 2017-03, Vol.176 (3), p.574-575

Coates, L.C.

2017

Volltextzugriff (PDF)

PCR65 Psychometric Assessment of the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from the Phase 3 BE OPTIMAL and BE COMPLETE Trials of Bimekizumab in Patients with Psoriatic Arthritis

Value in health, 2023-06, Vol.26 (6), p.S323-S323

2023

Volltextzugriff (PDF)

PCR229 Achieving Increasingly Stringent Disease Control Criteria Was Associated with Greater Quality of Life Improvements in Patients with Active Psoriatic Arthritis: Results from BE OPTIMAL and BE COMPLETE/BE VITAL up to 1 Year

Value in health, 2023-12, Vol.26 (12), p.S493

2023

Volltextzugriff (PDF)

Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)

British journal of dermatology (1951), 2013-04, Vol.168 (4), p.802-807

2013

Volltextzugriff (PDF)

SA64 Comparative Effectiveness of Bimekizumab in Patients with Psoriatic Arthritis: Results from a Systematic Literature Review and Network Meta-Analysis

Value in health, 2023-06, Vol.26 (6), p.S408-S408

2023

Volltextzugriff (PDF)

Différences selon le sexe sur les perceptions de l’impact du rhumatisme psoriasique, sa gestion et les interactions avec les médecins : résultats d’une enquête internationale auprès des patients

Revue du rhumatisme (Ed. française : 1993), 2023-12, Vol.90, p.A111

2023

Volltextzugriff (PDF)

Impact du bimékizumab sur les domaines évalués par le GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) chez les patients atteints de rhumatisme psoriasique (RhPso) : résultats à 52 semaines issus de 4 études de phase III

Revue du rhumatisme (Ed. française : 1993), 2023-12, Vol.90, p.A181-A183

2023

Volltextzugriff (PDF)

L’aprémilast améliore l’état des patients atteints du rhumatisme psoriasique de forme oligoarticulaire : analyse principale de l’essai thérapeutique contrôlé vs placebo FOREMOST

Revue du rhumatisme (Ed. française : 1993), 2023-12, Vol.90, p.A190

2023

Volltextzugriff (PDF)

THU0314 Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.375

2018

Volltextzugriff (PDF)

SAT0556 Methotrexate Efficacy in Early Psoriatic Arthritis – Open Label Data from the Ticopa Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.861-861

2015

Volltextzugriff (PDF)

Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results from a Real-World Survey in the USA and Europe

Rheumatology and therapy., 2022-02, Vol.9 (1), p.285-293

2022

Volltextzugriff (PDF)

SAT0336 Measurement properties of the minimal disease activity criteria for psoriatic arthritis

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1033

2018

Volltextzugriff (PDF)

Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis

Journal of the European Academy of Dermatology and Venereology, 2018-09, Vol.32 (9), p.1530-1534

2018

Volltextzugriff (PDF)

Natural history, definitions, risk factors and burden of otitis media

Medical journal of Australia, 2009-11, Vol.191 (S9), p.S39-S43

2009

Volltextzugriff (PDF)

SAT0406 Low Level of Erosive Change is Found in Early Psoriatic Arthritis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.741-742

2014

Volltextzugriff (PDF)

THU0419 Rapid3 Performs Well Identifying Treatment Effect in The Tight Control of Psoriatic Arthritis Study

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.340-341

2016

Volltextzugriff (PDF)

SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years’ treatment

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1027

2018

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(64)

Sprache

Englisch
(58)
Französisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation

Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update

Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017

PBI6 Stringent Thresholds of Disease Control Are Associated with Reduced Burden on Paid and Household Work Productivity in Patients with Psoriatic Arthritis during LONG-TERM Treatment with Certolizumab Pegol

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis

Psoriasis flare with corticosteroid use in psoriatic arthritis

Patient education and screening for psoriatic arthritis is key in the care of patients with psoriasis, whichever method is chosen

PCR65 Psychometric Assessment of the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from the Phase 3 BE OPTIMAL and BE COMPLETE Trials of Bimekizumab in Patients with Psoriatic Arthritis

PCR229 Achieving Increasingly Stringent Disease Control Criteria Was Associated with Greater Quality of Life Improvements in Patients with Active Psoriatic Arthritis: Results from BE OPTIMAL and BE COMPLETE/BE VITAL up to 1 Year

Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)

SA64 Comparative Effectiveness of Bimekizumab in Patients with Psoriatic Arthritis: Results from a Systematic Literature Review and Network Meta-Analysis

Différences selon le sexe sur les perceptions de l’impact du rhumatisme psoriasique, sa gestion et les interactions avec les médecins : résultats d’une enquête internationale auprès des patients

Impact du bimékizumab sur les domaines évalués par le GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) chez les patients atteints de rhumatisme psoriasique (RhPso) : résultats à 52 semaines issus de 4 études de phase III

L’aprémilast améliore l’état des patients atteints du rhumatisme psoriasique de forme oligoarticulaire : analyse principale de l’essai thérapeutique contrôlé vs placebo FOREMOST

THU0314 Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials

SAT0556 Methotrexate Efficacy in Early Psoriatic Arthritis – Open Label Data from the Ticopa Study

Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results from a Real-World Survey in the USA and Europe

SAT0336 Measurement properties of the minimal disease activity criteria for psoriatic arthritis

Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis

Natural history, definitions, risk factors and burden of otitis media

SAT0406 Low Level of Erosive Change is Found in Early Psoriatic Arthritis

THU0419 Rapid3 Performs Well Identifying Treatment Effect in The Tight Control of Psoriatic Arthritis Study

SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years’ treatment

Suchergebnisse filtern